📊 RLMD Key Takeaways
Is RLMD a Good Investment? Thesis Analysis
Relmada is a pre-commercial biotech company with emerging revenue ($5.2M) but catastrophic financial fundamentals: -$227.8M free cash flow burn, only $3.5M cash reserves, and $59.1M operating losses. With current burn rates, cash runway is measured in weeks without additional financing, creating severe dilution risk and viability concerns.
Why Buy RLMD? Key Strengths
- Revenue growing 93.7% YoY indicates emerging commercial traction
- Zero debt (Debt/Equity 0.00x) provides capital structure flexibility
- Stockholders' equity of $86.5M provides asset backing
RLMD Investment Risks to Consider
- Free cash flow of -$227.8M annually with only $3.5M cash creates critical runway crisis (weeks at current burn)
- Operating loss of $59.1M vs. $5.2M revenue shows no visible path to profitability or cash flow breakeven
- Capital expenditures of $182.1M indicate ongoing significant cash demands; no evidence of funded development pipeline
Key Metrics to Watch
- Monthly cash burn rate and months of runway remaining
- Clinical trial milestones, FDA approvals, and revenue-driving achievements
- Success in raising capital or reaching revenue inflection points
RLMD Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 14.62x current ratio provides a solid financial cushion.
RLMD Profitability Ratios
RLMD vs Healthcare Sector
How RELMADA THERAPEUTICS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RLMD Overvalued or Undervalued?
Based on fundamental analysis, RELMADA THERAPEUTICS, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RLMD Balance Sheet & Liquidity
RLMD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: RELMADA THERAPEUTICS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.65 indicates the company is currently unprofitable.
RLMD Growth Metrics (YoY)
RLMD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2014 | $682 | -$13.2K | N/A |
| Q1 2014 | $1.9K | -$9.0K | N/A |
| Q3 2013 | $400 | -$3.4K | N/A |
| Q2 2013 | $2.3K | -$942 | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RLMD Capital Allocation
RLMD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for RELMADA THERAPEUTICS, INC. (CIK: 0001553643)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RLMD
What is the AI rating for RLMD?
RELMADA THERAPEUTICS, INC. (RLMD) has an AI rating of STRONG SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RLMD's key strengths?
Claude: Revenue growing 93.7% YoY indicates emerging commercial traction. Zero debt (Debt/Equity 0.00x) provides capital structure flexibility.
What are the risks of investing in RLMD?
Claude: Free cash flow of -$227.8M annually with only $3.5M cash creates critical runway crisis (weeks at current burn). Operating loss of $59.1M vs. $5.2M revenue shows no visible path to profitability or cash flow breakeven.
What is RLMD's revenue and growth?
RELMADA THERAPEUTICS, INC. reported revenue of $5.2M.
Does RLMD pay dividends?
RELMADA THERAPEUTICS, INC. does not currently pay dividends.
Where can I find RLMD SEC filings?
Official SEC filings for RELMADA THERAPEUTICS, INC. (CIK: 0001553643) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RLMD's EPS?
RELMADA THERAPEUTICS, INC. has a diluted EPS of $-1.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RLMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, RELMADA THERAPEUTICS, INC. has a STRONG SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RLMD stock overvalued or undervalued?
Valuation metrics for RLMD: ROE of -66.3% (sector avg: 15%), net margin of -1,113.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RLMD stock in 2026?
Our dual AI analysis gives RELMADA THERAPEUTICS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RLMD's free cash flow?
RELMADA THERAPEUTICS, INC.'s operating cash flow is $-45.8M, with capital expenditures of $182.1M. FCF margin is -4,422.6%.
How does RLMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,113.9% (avg: 12%), ROE -66.3% (avg: 15%), current ratio 14.62 (avg: 2).